Milestone Pharmaceuticals
MIST
55 hedge funds and large institutions have $96.2M invested in Milestone Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 17 increasing their positions, 7 reducing their positions, and 15 closing their positions.
316% more call options, than puts
Call options by funds: $1.95M | Put options by funds: $468K
143% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 7
60% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 15
17% more funds holding
Funds holding: 47 → 55 (+8)
3.29% less ownership
Funds ownership: 73.21% → 69.92% (-3.3%)
52% less capital invested
Capital invested by funds: $199M → $96.2M (-$102M)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$13.4M |
| 2 |
BlackRock
New York
|
+$9.1M |
| 3 |
Millennium Management
New York
|
+$5.59M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.61M |
| 5 |
BL
Bleichroeder LP
New York
|
+$4.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$20.6M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$18.4M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$6.2M |
| 4 |
LPC
Lion Point Capital
New York
|
-$5.96M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
-$5.83M |
MIST Hedge Fund Activity: Q4 2022 in Review
55 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q4 2022, worth a combined $96.2M — down 52% from $199M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new MIST positions and 15 closed out — a net gain of 9 holders — while 17 added to existing stakes and 7 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $13.4M. The largest seller was RA Capital Management, exiting entirely with an estimated $20.6M sold.
- 55 institutional investors held Milestone Pharmaceuticals (MIST) as of Q4 2022, up from 47 in Q3 2022.
- Funds reported $96.2M of Milestone Pharmaceuticals stock for Q4 2022, down 52% quarter-over-quarter.
- 24 funds opened new Milestone Pharmaceuticals positions in Q4 2022 and 15 closed out, a net change of +9 holders.
- The largest Milestone Pharmaceuticals buyer in Q4 2022 was Goldman Sachs, an estimated $13.4M added.
- The largest Milestone Pharmaceuticals seller in Q4 2022 was RA Capital Management, an estimated $20.6M sold.
Based on aggregated 13F filings for Q4 2022.